Table 1.
Baseline Characteristics of Participants for Myocarditis Analyses by Vaccine Product
| BNT162b2 (n = 2,223,454) | mRNA-1273 (n = 871,960) | Standardized Mean Difference | |
|---|---|---|---|
| Dose interval, da | 64.0 (57.0, 76.0) | 62.0 (54.0, 73.0) | 0.160 |
| Age, y | 50.0 (34.0, 67.0) | 51.0 (34.0, 66.0) | 0.002 |
| Age category, y | 0.035 | ||
| 18-29 | 397,586 (17.8) | 147,176 (16.8) | |
| 30-39 | 370,445 (16.6) | 146,034 (16.7) | |
| 40-49 | 318,242 (14.3) | 119,955 (13.7) | |
| ≥50 | 1,137,181 (51.1) | 458,795 (52.6) | |
| Sex | 0.058 | ||
| Male | 1,028,494 (46.3) | 428,691 (49.2) | |
| Female | 1,194,960 (53.7) | 443,269 (50.8) | |
| Comorbidities | |||
| Alzheimer’s/dementia | 24,966 (1.1) | 9,351 (1.1) | 0.005 |
| Anxiety | 758,386 (34.1) | 294,790 (33.8) | 0.006 |
| Schizophrenia | 20,843 (0.9) | 8,288 (0.9) | 0.001 |
| Depression | 619,867 (27.9) | 242,067 (27.8) | 0.003 |
| Ischemic heart disease | 173,739 (7.8) | 64,565 (7.4) | 0.015 |
| Heart failure | 54,328 (2.4) | 20,051 (2.3) | 0.009 |
| Hypertension | 552,464 (24.8) | 211,275 (24.2) | 0.014 |
| Asthma | 271,995 (12.2) | 104,078 (11.9) | 0.009 |
| Chronic obstructive pulmonary disease | 86,349 (3.9) | 35,126 (4.0) | 0.007 |
| Chronic kidney disease | 89,936 (4.0) | 32,018 (3.7) | 0.019 |
| Diabetes | 247,959 (11.1) | 96,763 (11.1) | 0.002 |
| Gout | 70,297 (3.2) | 27,153 (3.1) | 0.003 |
| Hemorrhagic stroke | 4,183 (0.2) | 1,669 (0.2) | 0.001 |
| Ischemic stroke | 14,799 (0.7) | 5,633 (0.6) | 0.002 |
| Epilepsy | 19,853 (0.9) | 8,187 (0.9) | 0.005 |
| Multiple sclerosis | 5,701 (0.3) | 2,400 (0.3) | 0.004 |
| Osteoarthritis | 274,923 (12.4) | 107,843 (12.4) | <0.001 |
| Osteoporosis | 113,350 (5.1) | 36,725 (4.2) | 0.042 |
| Rheumatoid arthritis | 35,451 (1.6) | 13,799 (1.6) | 0.001 |
| Injection drug use | 59,031 (2.6) | 24,569 (2.8) | 0.010 |
| Alcohol misuse | 73,168 (3.3) | 33,705 (3.9) | 0.031 |
| Cirrhosis | 10,287 (0.5) | 4,575 (0.5) | 0.009 |
| Cancer | 370,406 (16.7) | 135,703 (15.6) | 0.030 |
| Immunosuppression | 46,003 (2.1) | 16,271 (1.9) | 0.015 |
| Any comorbidity | 1,401,266 (63.0) | 543,098 (62.3) | 0.015 |
| Prevaccination SARS-CoV-2 infection | 61,392 (2.8) | 23,414 (2.7) | 0.005 |
Values are median (Q1, Q3) or n (%).
a
Interval between 2 vaccine doses in days.